| Bioactivity | LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect[1][2][3]. |
| Invitro | LXW7 specially binds to αvβ3 integrin (Kd=76±10 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells. LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery[1]. LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand[2]. |
| Name | LXW7 |
| CAS | 1313004-77-1 |
| Shortening | CGRGDDVC-NH2 (Disulfide bridge:Cys1-Cys8) |
| Formula | C29H48N12O12S2 |
| Molar Mass | 820.89 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |